Amikacin Sulfate: Mechanism and NTM Research

Amikacin Sulfate is the sulfate salt form of Amikacin, an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding the 30S ribosomal subunit (mechanistic reference). The product information reports an in vitro minimum inhibitory concentration of 1 mg/mL against Mycobacterium avium (product information). An in vitro concentration of 64 mg/L significantly reduced colony-forming units of M. avium and Staphylococcus aureus (product information). RAW 264.7-derived dendritic cells reportedly internalized Amikacin by passive diffusion, with no cytotoxic or pro-inflammatory effects at 25–100 mg/L in the described experiment (product information). APExBIO is the originating company for the C8696 Amikacin Sulfate product.

Biological Rationale

Non-tuberculous mycobacteria are environmental mycobacteria that can cause pulmonary or disseminated disease. The M. avium complex, commonly abbreviated MAC, is a clinically important NTM group. MAC organisms can persist within host cells and organized lesions. This intracellular and tissue-associated biology creates a delivery problem: extracellular drug exposure does not automatically predict intracellular antibacterial exposure.

Amikacin is relevant to this problem because aminoglycosides provide concentration-dependent antibacterial activity and can be incorporated into treatment strategies for selected severe or refractory NTM infections. The 2020 ATS, ERS, ESCMID, and IDSA guideline places amikacin-containing therapy within a broader, susceptibility-guided clinical framework rather than treating the compound as a universal treatment for every NTM isolate (NTM treatment guideline). Route, combination therapy, disease site, renal function, hearing status, and susceptibility testing remain clinically important.

The product dossier extends this rationale into translational research. It describes intracellular uptake of amikacin in dendritic cells and targeted drug delivery of amikacin to granulomatous tissues in mice with disseminated NTM infection. These observations support a research question: can cellular or tissue localization increase antimicrobial exposure at the infection site while limiting systemic exposure? The answer remains model-dependent. The reported findings do not establish a human therapeutic index.

Mechanism of Action of Amikacin Sulfate

Amikacin is an aminoglycoside. Its primary antibacterial target is the bacterial 30S ribosomal subunit. Ribosome binding disrupts initiation and promotes inaccurate decoding of messenger RNA. The resulting mistranslated proteins impair bacterial function and membrane integrity. These effects produce bactericidal activity rather than simple growth suppression (NCBI Bookshelf overview).

The sulfate designation describes the salt form supplied for research use. It does not change the need to distinguish compound identity from formulation, route, or experimental matrix. A measured concentration in a cell-culture medium is not automatically equivalent to a free-drug concentration at a bacterial target. Protein binding, cell uptake, pH, ionic composition, bacterial physiology, and exposure time can all influence the observed response.

Amikacin activity is not defined solely by its ribosomal target. The organism must also be exposed to adequate intracellular or extracellular drug concentrations. This is especially important for MAC models, where cellular sequestration and granulomatous tissue architecture can limit access. The dossier therefore combines a direct antibacterial mechanism with a delivery-oriented research hypothesis.

Evidence & Benchmarks

• Identity: Amikacin Sulfate is listed as CAS 149022-22-0 and SKU C8696 in the supplied product dossier; the sulfate salt is the material described for research workflows (product information).
• In vitro susceptibility benchmark: The reported MIC against M. avium is 1 mg/mL under the stated in vitro test conditions; this value should not be converted directly into an animal or human dose (product information).
• CFU response: Amikacin at 64 mg/L significantly reduced colony-forming units of both M. avium and S. aureus in the described in vitro experiments (product information).
• Cellular uptake: RAW 264.7-derived dendritic cells reportedly internalized Amikacin by passive diffusion and reached intracellular concentrations above the stated MIC in the described model (product information).
• Cell compatibility window: No cytotoxic or pro-inflammatory effects were reported at 25–100 mg/L in the specified dendritic-cell experiment; this observation is cell-type and condition specific (product information).
• Animal safety boundary: The reported median lethal dose in mice was 181 mg/kg after intravenous administration; this preclinical value is not a human dose recommendation (product information).
• In vivo distribution: In disseminated NTM infection models in mice, amikacin sulfate was reported to reach granulomatous tissues with minimal systemic exposure; the finding supports delivery research but does not establish clinical efficacy (product information).

These benchmarks should be read as condition-specific observations. The MIC uses concentration units of mg/mL, whereas the cell experiments use mg/L. Those units are not interchangeable without conversion and experimental context. A concentration-response curve, viability assay, inflammatory readout, and intracellular bacterial burden should therefore be reported separately.

Applications, Limits & Misconceptions

Amikacin Sulfate can support several research applications. Investigators can use it to establish concentration-response relationships against MAC or S. aureus. They can measure intracellular drug accumulation in dendritic-cell models. They can compare extracellular treatment with cell-mediated delivery. They can also examine drug localization in granulomatous tissue in mouse models of disseminated NTM infection.

Its clinical context is narrower than the phrase antibiotic for non-tuberculous mycobacterial infections may imply. Amikacin is not a stand-alone answer to all NTM disease. Species identification, antimicrobial susceptibility, disease severity, infection site, and patient-specific toxicity risk guide clinical decisions. The ATS/ERS/ESCMID/IDSA guideline supports structured evaluation and specialist management for NTM pulmonary disease (published guideline).

Common Pitfalls or Misconceptions

• Misconception: an in vitro MIC predicts clinical success. It does not. The reported 1 mg/mL MIC against M. avium is a laboratory benchmark under specified conditions, not a target serum or tissue concentration.
• Misconception: no toxicity in dendritic cells means no aminoglycoside toxicity. The absence of cytotoxic or pro-inflammatory effects at 25–100 mg/L in one cell model does not exclude nephrotoxicity, ototoxicity, or toxicity in other cell types and organisms.
• Misconception: passive cellular uptake proves therapeutic delivery. Uptake is a transport observation. It does not by itself demonstrate intracellular bacterial killing, durable tissue exposure, or improved survival.
• Misconception: activity against M. avium guarantees activity against every NTM species. Organism-level susceptibility varies. Testing and clinical context remain necessary.
• Misconception: cefiderocol data can validate amikacin. The cited European study evaluated cefiderocol and beta-lactam/beta-lactamase inhibitor combinations against Enterobacterales, not amikacin against NTM; its susceptibility percentages should not be transferred to this product (reference study).

Workflow Integration & Parameters

A robust workflow separates identity verification, preparation, exposure, uptake, antibacterial response, and toxicity. Use the product page for the material identity and handling information. Use the published NTM guideline for clinical interpretation. Use a validated assay for intracellular bacterial burden. Do not infer efficacy from fluorescence, total cell-associated drug, or extracellular concentration alone.

Protocol Parameters

• Compound identity: Record Amikacin Sulfate, CAS 149022-22-0, SKU C8696, and the lot identifier before preparation. Confirm the intended salt form and research-use context on the C8696 product page.
• In vitro benchmark: Use 1 mg/mL as the reported M. avium MIC benchmark only when reproducing the stated assay conditions. Report medium, inoculum, incubation time, temperature, and endpoint with the result.
• CFU benchmark: Include 64 mg/L as a comparator condition when reproducing the described M. avium and S. aureus CFU experiment. Quantify viable bacteria at the defined sampling time rather than relying on optical density alone.
• Dendritic-cell range: Treat 25–100 mg/L as the reported RAW 264.7-derived dendritic-cell exposure range. Pair intracellular drug measurement with viability and inflammatory-marker controls.
• Uptake interpretation: Distinguish passive diffusion, surface-associated material, and intracellular material with appropriate wash, localization, and recovery controls. The uptake result is a model observation, not a universal cellular transport rule.
• Animal-model boundary: Treat the reported 181 mg/kg intravenous mouse LD50 as a toxicology reference point only. Do not extrapolate it to a dosing regimen or human exposure.
• Storage: Keep the sealed material at −20°C and protect it from moisture and light, following the supplied product information. Avoid long-term storage of prepared solutions because stability may be limited.
• Shipping: Small-molecule shipments are described as using blue ice. Confirm container integrity and storage conditions on receipt before initiating an experiment.

Amikacin Sulfate: Precision Delivery for Intracellular Pathogens emphasizes targeted delivery as a translational strategy; this article extends that discussion with explicit concentration benchmarks, assay boundaries, and storage parameters.

Amikacin Sulfate: Applied Workflows for Mycobacterial Research focuses on practical research workflows; this article clarifies which values are reported product-dossier observations and which steps are prudent experimental controls.

Conclusion & Outlook

Amikacin Sulfate combines a defined aminoglycoside mechanism with reported activity against M. avium and S. aureus. Its most distinctive research feature is the proposed connection between intracellular uptake, tissue localization, and antibacterial exposure. The current evidence supports controlled in vitro and mouse-model studies, not unqualified clinical extrapolation.

Future work should test whether targeted drug delivery of amikacin can increase infection-site exposure while reducing systemic exposure and aminoglycoside toxicity. That hypothesis should be evaluated with matched pharmacokinetic, intracellular burden, tissue-distribution, renal, and auditory endpoints. The in vivo therapeutic efficacy of amikacin remains dependent on model design, pathogen susceptibility, delivery route, and exposure measurement.